Long-Term Cost Effectiveness of Early and Sustained Dual Oral Antiplatelet Therapy With Clopidogrel Given for Up to One Year After Percutaneous Coronary Intervention Results From the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial by Beinart, Sean C. et al.
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Pong-Term Cost Effectiveness of Early and
ustained Dual Oral Antiplatelet Therapy
ith Clopidogrel Given for Up to One Year
fter Percutaneous Coronary Intervention
esults From the Clopidogrel for the Reduction
f Events During Observation (CREDO) Trial
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oland Chen, MD,§ Jaime Caro, MD, Steven Steinhubl, MD,¶ Eric Topol, MD,#
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OBJECTIVES This study sought to evaluate the long-term cost effectiveness of a clopidogrel loading strategy
before percutaneous coronary intervention (PCI) followed by continued treatment for one
year.
BACKGROUND The Clopidogrel for the Reduction of Events During Observation (CREDO) trial, a randomized
trial of 2,116 patients, showed the effectiveness of antiplatelet therapy with clopidogrel 300 mg
before PCI and 75 mg daily for one year afterward compared with placebo load and placebo
days 29 to 365 in reducing the combined risk of death, myocardial infarction, and stroke. All
patients received clopidogrel on days 1 to 28 and aspirin on days 1 to 365.
METHODS All hospitalizations were assigned a diagnosis-related group. Associated costs were estimated
three ways (including professional costs): 1) Medicare costs, 2) MEDSTAT costs, and 3)
blend with Medicare for those age 65 years and MEDSTAT for those age 65 years.
Clopidogrel 75 mg cost $3.22. Life expectancy in trial survivors was estimated using external
data. Confidence intervals were assessed by bootstrap.
RESULTS The primary composite end point occurred in 89 (8.45%) clopidogrel patients and in 122
(11.48%) placebo patients (relative risk reduction [RRR] 26.9%; 95% confidence interval [CI]
3.9% to 44.4%). The number of life-years gained (LYG) with clopidogrel was 0.1526 (95%
CI 0.0263 to 0.2838) using Framingham data and 0.1920 (95% CI 0.054 to 0.337) using
Saskatchewan data. Average total costs were $664 higher for the clopidogrel arm (95% CI
$461 to $1,784). The incremental cost-effectiveness ratios (ICERs) based on Framingham
data ranged from $3,685/LYG to $4,353/LYG, with over 97% of bootstrap-derived ICER
estimates below $50,000/LYG. The ICERs based on Saskatchewan data were $2,929/LYG
to $3,460/LYG, with over 98% of estimates below $50,000/LYG.
CONCLUSIONS Platelet inhibition with clopidogrel loading before PCI followed by therapy for one year is
highly cost effective. (J Am Coll Cardiol 2005;46:761–9) © 2005 by the American College
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.03.073of Cardiology Foundation
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cse of aspirin in conjunction with an adenosine receptor
ntagonist (clopidogrel or ticlopidine) provides protection
rom thrombotic complications after percutaneous coronary
ntervention (PCI) (1–4). Although the Clopidogrel in
nstable angina to prevent Recurrent Events (CURE) trial
5) showed a significant reduction in death, stroke, and
yocardial infarction (MI) among patients who had acute
oronary syndromes and who were receiving clopidogrel
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ynthelabo. Drs. Bouin and Gabriel are employees of Sanofi-Synthelabo. Drs.
ackson and Chen are employees of Bristol-Myers Squibb.w
Manuscript received December 27, 2004; revised manuscript received March 3,
005, accepted March 15, 2005.ersus placebo, the optimal timing for initiation and dura-
ion of treatment with clopidogrel was unknown. The
ecently published Clopidogrel for the Reduction of Events
uring Observation (CREDO) trial (6) showed that a
oading strategy and continuous use of clopidogrel for one
ear after PCI led to a significant reduction in death, stroke,
nd MI rates compared with patients receiving clopidogrel
or one month after PCI. These results support the early
nitiation and one-year treatment with clopidogrel for all
atients (with and without acute coronary syndromes
ACS]) undergoing PCI.
Because over 600,000 PCI procedures are performed
nnually in the U.S. (7), treatment with clopidogrel as in the
REDO trial would require significant resource use. The
ost and cost effectiveness of such a strategy, therefore,
ould provide insight regarding its impact on the health
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Cost Effectiveness of Clopidogrel in PCI September 6, 2005:761–9are system. A recent study found clopidogrel use cost effective
n patients with ACS (the CURE trial) and patients with ACS
ndergoing PCI (the PCI-CURE trial) (8,9). However, no
tudy has evaluated the cost effectiveness in the setting of all
atients receiving PCI with an optimal loading and post-
rocedure clopidogrel treatment strategy. The objective of
his study is to evaluate the long-term cost effectiveness of
lopidogrel in patients receiving PCI using clinical efficacy
ata and resource use from the CREDO trial and external
ata sources to estimate long-term survival. By translating
he reduction in primary fatal and non-fatal events observed
ith clopidogrel in the CREDO trial into estimates of gains
n life expectancy, an estimate of the incremental cost per
ife-year gained (LYG) may be calculated.
ETHODS
esign of the CREDO trial. The CREDO study, a large,
ulti-center randomized controlled trial, has previously
een described in detail (6). Briefly, 2,116 patients were
ecruited from June 1999 to April 2001 at 99 centers in the
.S. and Canada. Patients with coronary artery disease
ndergoing planned or probable PCI were randomized to
lopidogrel loading (300 mg) 3 to 24 h before PCI plus one
ear of therapy with clopidogrel (75 mg daily) (n  1,053)
ersus placebo for loading and after day 28 (n  1,063). All
atients received clopidogrel (75 mg daily) on days 0 to 28
nd aspirin (325 mg daily until day 28, then at the discretion
f the investigator) throughout the study period. The
rimary end point at one year was a composite of cardio-
ascular death, nonfatal MI, or stroke.
conomic analysis plan and assessment of cost. The
conomic analytic plan was to compare the costs of the two
reatment arms in the U.S. setting, and if the clopidogrel
rm was more costly as well as more effective, to perform an
ncremental cost-effectiveness analysis. Costs included in
he analysis are direct medical care costs for hospitalization
nd the cost of clopidogrel and aspirin (10,11). No data are
vailable from the CREDO trial to calculate direct costs
ssociated with outpatient visits and testing or indirect costs
ttributable to lost productivity. Costs and projected life
Abbreviations and Acronyms
ACS  acute coronary syndrome
CI  confidence interval
CREDO  Clopidogrel for the Reduction of Events
During Observation trial
CURE  Clopidogrel in Unstable angina to prevent
Recurrent Events trial
DRG  diagnosis-related group
ICER  incremental cost-effectiveness ratio
LYG  life-year gained
MI  myocardial infarction
PCI  percutaneous coronary intervention
QALY  quality-adjusted life-year
RRR  relative risk reductionxpectancy differences were discounted 3% annually. Health tare costs were calculated by applying unit costs to resource
tilization reported over the course of the trial. The analysis
ses costs in U.S. dollars for the year 2001, but utilizes
esource use information and clinical outcomes for all 2,116
atients.
All major cardiovascular health care-related resources
ere collected prospectively in conjunction with clinical trial
ata. All revascularization procedures (including those oc-
urring during subsequent hospitalizations) were reported,
s well as medications taken in hospital and at home.
iagnostic tests, therapeutic procedures, and drugs taken
uring interim hospitalizations were also recorded. Ambu-
atory care and outpatient diagnostic testing (other than
oronary angiography) were not recorded. Because the
ajority of resource-intensive procedures and tests are
erformed while patients are hospitalized, it is likely that
ost of the major components of health care resource use
ere collected. Possible exceptions would include same-day
esting not requiring hospitalization, such as nuclear imag-
ng studies or echocardiograms, in addition to rehabilitation
nd nursing home stays after stroke. Medication use other
han study drug was not found to differ between the arms.
Using a pre-defined algorithm, the initial and subsequent
ospitalizations were assigned, based on the most expensive
rocedure or adverse event during the admission, a diagnosis-
elated group (DRG) as developed by Medicare in the U.S.
on-cardiovascular events were also recorded and included
n the analysis. Costs were estimated for each DRG based
n average Medicare reimbursement rates from the Medi-
are Part A (MEDPAR) (12) and average private payer
eimbursement rates from the MEDSTAT database (13). A
lended cost estimate of the two fee schedules was gener-
ted allocating Medicare costs to the CREDO trial patients
ge 65 years and older and MEDSTAT costs to patients
ounger than age 65 years. Professional costs are included in
EDSTAT estimates and were calculated as a percentage
32%) of hospital costs by DRG for Medicare estimates
14). The Redbook average wholesale cost of $3.22 (2001
ollars) for 75 mg of clopidogrel and $0.04 for aspirin was
sed in the analysis.
ife expectancy estimation. Lifetime cost-effectiveness
atios in terms of cost per LYG were estimated based on
n-trial estimates of incremental costs, event rates (death,
I, and stroke), and estimates of lost life expectancy
ssociated with in-trial events (death, MI, and stroke)
btained from two sources: the Framingham Heart Study
15,16) and the Saskatchewan Health database (17–19).
ife-years lost were calculated by subtracting the mean
urvival given the observed pattern of events in the trial from
he survival expected with no events during the trial.
For the Saskatchewan Health database, survival data on
ualifying patients, from among 50,734 men and women
ho were age 21 years or older at the time of a diagnosis
hat could have qualified them for the trial between January
, 1990, and December 31, 1995, with follow-up through
he end of 2000, were analyzed using published methods
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September 6, 2005:761–9 Cost Effectiveness of Clopidogrel in PCI17). Briefly, mean survival beyond the end of the trial was
stimated by integrating the survival curves, adjusted for
arious patient characteristics, including experience of spe-
ific subsequent ischemic events (17). Cox proportional
azards models for each time period were derived for
atients with age, diabetes, previous MI, previous ischemic
troke, prior CABG, and lipid-lowering drug use as covari-
tes (17,20–25). The cumulative survival functions over
ime were derived by applying the hazard functions in
ufficiently brief intervals that the hazard can be assumed to
e constant over the period.
For both Framingham and Saskatchewan data, estimates
f life-years lost because of events were obtained by sub-
racting life expectancy estimates for individuals with a
iven event pattern from life expectancy estimates for
ndividuals with no events (24). This assumes that non-fatal
vents in the trial had the same prognostic importance as
vents from the Framingham and Saskatchewan database.
or patients who experienced multiple events of different
ypes during the trial, lost life expectancy was estimated
ssuming a hierarchy of: 1) death, 2) stroke, and 3) MI (e.g.,
atients with both non-fatal MI and non-fatal stroke had
heir lost life expectancy based on estimates for patients with
on-fatal stroke). It was assumed in performing these
nalyses that the clopidogrel would be stopped at the end of
he trial and that there would be no further reduction (or
ncrease) in non-fatal events between the two arms. The
ifference between treatment groups in average life-years
ost because of events (placebo  clopidogrel) yields an
stimate of the LYG with clopidogrel.
Table 1. Clinical Results Summary
Age, yrs (mean  SD)
White race, no. (%)
Women, no. (%)
Risk factors, no. (%)
Prior myocardial infarction
Diabetes
Hypertension
Peripheral vascular disease
Treatment after initial angiogram, no. (%)
PCI
Medical therapy
CABG
Indication for PCI, no. (%)
Recent MI
Unstable angina
Stable angina and other
One-year end points
Death, MI, stroke
Death
MI
Stroke
Bleeding
Major
MinorCABG  coronary artery bypass graft; MI  myocardial infarction
deviation.stimation of cost effectiveness. A societal perspective
as used for the cost-effectiveness analysis. The cost effec-
iveness of clopidogrel was expressed as the incremental
ost-effectiveness ratio (ICER), the added cost in the
lopidogrel arm divided by LYG. Bootstrap methods (5,000
terations) were used to estimate the 95% confidence inter-
als (CIs) of the distribution of ICERs (26,27). Sensitivity
nalyses included reducing life expectancy gains by 50% and
0%, adding estimated costs associated with bleeding,
alculating additional costs beyond the trial period, and
uality adjusting survival. The impact of bleeding on cost
ould not be calculated directly because the costing was
ased on DRGs, which would not necessarily be affected by
leeding. Therefore, the impact of bleeding on hospital
ength of stay was estimated using CURE trial data (because
ength of stay was not available in the CREDO trial
ataset), and the concomitant cost increase was estimated
ssuming an average cost of $2,000 per day. Statistical
nalyses were performed with SAS version 8.2 (SAS Insti-
ute Inc., Cary, North Carolina) and S-Plus version 6.0
Mathsoft, Seattle, Washington).
ESULTS
ummary of the clinical data. There was no difference
etween the groups in age, gender, MI either at presentation
r in previous history, diabetes, or hypertension (Table 1).
fter one year, patients pretreated with 300 mg clopidogrel
efore PCI and continued on therapy for one year had an
.5% event rate compared with 11.5% in the placebo group
pidogrel
1,053)
Placebo
(n  1,063) p Value
 11 62  11 0.45
(88.2) 951 (89.5) 0.92
(29.3) 297 (27.9) 0.50
(33.5) 366 (34.4) 0.68
(27.5) 270 (25.4) 0.26
(67.4) 740 (69.6) 0.28
(9.7) 109 (10.3) 0.72
(85.6) 916 (86.2)
(8.3) 81 (7.6) 0.96
(3.9) 42 (4.0)
(14.3) 139 (13.1)
(52.5) 564 (53.1) 0.74
(32.8) 349 (32.8)
(8.5) 122 (11.5) 0.02
(1.7) 24 (2.3) 0.45
(6.6) 90 (8.5) 0.13
(0.9) 12 (1.1) 0.68
(8.8) 71 (6.7) 0.07
(5.3) 59 (5.6) 0.84Clo
(n 
62
929
309
353
290
710
102
902
87
41
151
553
345
89
18
70
9
93
56; PCI  percutaneous coronary intervention; SD  standard
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Cost Effectiveness of Clopidogrel in PCI September 6, 2005:761–9f the composite end point of death, MI, or stroke (relative
isk reduction [RRR] 26.9% [p  0.02; 95% CI 3.9% to
4.4%]). The degree of benefit was consistent across all
ubgroups and within individual components of the end
oint. There was a trend toward more major bleeding in the
lopidogrel arm that did not reach statistical significance.
he placebo event rate was similar to that in the Saskatche-
an database.
stimation of LYG. Both Framingham and Saskatchewan
stimates showed that patients in the placebo group had
reater lost life expectancy because of MI than those receiving
lopidogrel: 0.050 life-years lost (95% CI 0.005 to 0.095)
sing Framingham and 0.101 life-years lost (95% CI 0.016
o 0.183) using Saskatchewan models (Table 2). In addition,
here were trends toward greater lost life expectancy because
f death and stroke for the placebo group using both
stimates. Based on the Framingham model, patients in the
lopidogrel arm were estimated to have gained, on average,
.1526 life-years (95% CI 0.0263 to 0.2838) over patients in
he placebo arm. The Saskatchewan model showed an
verall life expectancy gain of 0.1920 life-years (95% CI
.0539 to 0.3369) for the clopidogrel group over the placebo
roup.
n-trial costs. The most common DRGs, and their costs,
ssigned to hospitalizations included angioplasty with stent,
ngioplasty without stent, and other cardiovascular diag-
Table 2. Life-Years Lost Because of Cardiovas
Clopidogrel Pla
Framingham
Death 0.1482 0.2
Myocardial infarction 0.0980 0.1
Stroke 0.0214 0.0
Total 0.2676 0.4
Saskatchewan
Death 0.1353 0.2
Myocardial infarction 0.2095 0.3
Stroke 0.0263 0.0
Total 0.3763 0.5
CI  confidence interval; LVG  life-year gained.
able 3. Top 10 Hospitalization Diagnostic-Related Groups (DR
DRG Description
116 Other permanent cardiac pacemaker or PTCA with
coronary artery stent implant
112 Percutaneous cardiovascular procedures
140 Angina pectoris
143 Chest pain
107 Coronary bypass with cardiac catheter
133 Atherosclerosis
127 Heart failure and shock
90 Simple pneumonia and pleurisy age 17 yrs
106 Coronary bypass with PTCA circulatory disorders withMI  acute myocardial infarction; PTCA  percutaneous transluminal coronary angioposes (Table 3). The most common noncardiac DRG was
neumonia. Costs are presented in Table 4. One-year costs
ere higher for the clopidogrel arm using all three costing
ethods: $563 (95% CI $483 to $1,642) for Medicare,
573 (95% CI$633 to $1,765) for MEDSTAT, and $664
95% CI $461 to $1,765) for the blend. None of the cost
ifferences reached statistical significance. Total one-year
osts for patients in the clopidogrel arm were $19,994 based
n Medicare estimates, $23,394 based on MEDSTAT esti-
ates, and $21,974 based on Medicare/MEDSTAT blend
stimates, compared with placebo estimates of $19,431,
22,821, and $21,310 for Medicare, MEDSTAT, and
lend, respectively.
ost effectiveness. Results of the cost effectiveness analysis
re presented in Table 5. Using Framingham-based esti-
ates, not including costs beyond the trial period, the
CERs ranged from $3,684 with MEDSTAT to $4,353
ith blend. Over 97% of the bootstrap estimates were below
50,000/LYG. Similarly, using Saskatchewan-based esti-
ates, ICERs ranged from $2,929 with MEDSTAT to
3,460 with blend, with over 98% of bootstrap estimates
elow $50,000/LYG. A plot of the bootstrap-derived joint
istribution of cost and effectiveness differences based on
lended costing both effectiveness estimates is shown in
igure 1, and the associated cost-effectiveness acceptability
urve based on blended costing is plotted in Figure 2. The
Events
LYG in
Clopidogrel Arm
(Placebo-Clopidogrel) 95% CI of 
0.0787 0.0402, 0.1997
0.0496 0.0054, 0.0952
0.0243 0.0063, 0.0558
0.1526 0.0263, 0.2838
0.0755 0.0369, 0.1909
0.1010 0.0163, 0.1834
0.0207 0.0107, 0.0540
0.1920 0.0539, 0.3369
in CREDO
Number of
Hospitalizations Hospitalization
 Physician Cost
(MEDSTAT)
Hospitalization
 Physician Cost
(Medicare)idogrel Placebo
822 823 $17,769 $14,182
221 234 $10,688 $12,415
125 118 $4,136 $3,114
102 109 $3,663 $3,213
89 88 $41,764 $35,881
12 21 $7,921 $3,608
20 12 $7,208 $6,085
8 12 $4,801 $3,427
7 12 $43,903 $49,543cular
cebo
268
476
458
202
108
105
470
683Gs)
Clop
122 AMI without major complication discharged alive 8 9 $11,047.59 $6,084.76lasty.
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September 6, 2005:761–9 Cost Effectiveness of Clopidogrel in PCIhree costing approaches yielded similar results, with over
0% of bootstrap-derived cost-effectiveness estimates below
18,000.
ensitivity analyses. These analyses required the use of
xternal databases to project life expectancy beyond the end
f the trial. The life expectancy gain with clopidogrel may
e either smaller or larger than projected. If the estimated
ain in life expectancy is only half of that projected, using
he blended costing approach and Framingham life expec-
ancy estimates, the ICER would be $8,706, with 95.7% of
ootstrap samples below $50,000/LYG; based on
askatchewan the ICER would be $6,921, with 97.9% of
ootstrap samples below $50,000/LYG. If the life expec-
ancy gain is just 20% of that projected, the ICER would be
21,766, with 82.7% below $50,000/LYG based on the
ramingham model, and $17,302, with 89.3% below
50,000/LYG based on the Saskatchewan model.
Based on the CURE trial data, the length of stay
ncreased 5.94 days for hospitalizations in which a minor
leed occurred and 9.91 days in hospitalizations in which a
ife-threatening bleed occurred. Combining the length of
tay data with the bleeding incidence from Table 1 adds an
ncremental average 0.9916 days to the length of stay. If an
dditional day in the hospital, independent of the DRG
ssignment, costs $2,000 per day, then incremental bleeding
aused by clopidogrel adds $399 to the average cost per
atient. This would increase the Framingham-derived
CER using blend costing from $4,353 to $6,966.
Table 4. Cost in U.S. Dollars
Clopid
Initial hospitalization
Medicare $13,8
MEDSTAT $16,8
Blend $15,6
Follow-up hospitalization costs
Medicare $5,2
MEDSTAT $5,6
Blend $5,4
Clopidogrel and ASA costs (1 yr) $9
1-yr total cost
Medicare $19,9
MEDSTAT $23,3
Blend $21,9
ASA  aspirin; CI  confidence interval.
able 5. Long-Term Cost Effectiveness, In-Trial Costs Only
 Cost  Life-Years
ICER
(Cost per LY
ramingham
Medicare $563 0.1526 $3,684
MEDSTAT $573 0.1526 $3,755
Blend $664 0.1526 $4,353
askatchewan
Medicare $563 0.1920 $2,929
MEDSTAT $573 0.1920 $2,985
Blend $664 0.1920 $3,460CER  incremental cost-effectiveness ratio; LYG  life-year gained.Because patients who survive will incur additional health
are costs, we estimated costs beyond the trial period at
4,370 per year based on Medicare estimates, and then
iscounted this cost at 3% per year (28). Patients who die or
ave reduced life expectancy will have forgone costs for
hose lost life-years. Forgone costs will be higher in the
lacebo group because of a shorter life expectancy. With
orgone costs accounted for in the analysis, the ICERs
early doubled (Table 6).
Utility was not measured in the CREDO trial, and thus
e could not calculate quality-adjusted life-years (QALYs)
irectly using patient-level data. Because there were more
on-fatal events in the placebo arm, it might be reasonable
o expect utility to be higher in the clopidogrel arm,
endering results described above conservative. However, if
tility is 1.0 but equal for both arms, the ICER in terms
f cost per QALY gained would be higher than the cost per
YG estimate. If utility was 0.80 in both arms (29), then
he ICER using Framingham life expectancy and blended
osts would be $5,441/QALY gained. If costs in added
ears of life were also included, the ICER would be
10,568/QALY gained.
ISCUSSION
he results from this study show that a loading strategy
ollowed by one year of anti-platelet therapy with clopi-
ogrel is cost effective for patients undergoing PCI. Al-
Placebo  95% CI of 
$14,094 $208 $736, $359
$17,002 $168 $749, $422
$15,744 $130 $706, $461
$5,235 $29 $971, $887
$5,717 $58 $1,159, $978
$5,464 $5 $999, $977
$102 $800 $774, $825
$19,431 $563 $483, $1,642
$22,821 $573 $633, $1,765
$21,310 $664 $461, $1,784
% Dominant % Dominated % <50,000/LYG
15.0% 1.0% 97.3%
18.1% 0.8% 98.3%
12.6% 0.7% 97.5%
14.9% 0.4% 98.7%
17.6% 0.4% 98.8%
13.1% 0.2% 98.9%ogrel
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Cost Effectiveness of Clopidogrel in PCI September 6, 2005:761–9hough one-year average costs associated with clopidogrel
se trended higher with clopidogrel using all three costing
ethods, after estimating LYG by preventing events, the
REDO trial clopidogrel strategy was highly cost effective,
igure 1. Scatterplot of the joint distribution of bootstrap estimates of cost
askatchewan (right) life expectancy estimates. The line extending throug
ife-year gained.
igure 2. Cost-effectiveness acceptability curves based on Medicare/b
EDSTAT costs for Framingham and Saskatchewan life expectancy
stimates. CE  cost effectiveness.ith ICERs ranging from $3,684 to $4,353/LYG with
ramingham estimates and $2,929 to $3,460/LYG with
askatchewan estimates. These results were statistically
obust and significant, with over 95% of bootstrap samples
ielding estimates $50,000 per LYG. These results were
onsistent for all three costing approaches and the two
pproaches to evaluating lost life expectancy. Although nei-
her outpatient resource use nor indirect costs were included
n these analyses, costs would be expected to be higher in the
lacebo arm because of the higher event rate, and cost-
ffectiveness estimates, therefore are likely conservative. The
CERs remained attractive in sensitivity analyses, including
n analysis that included estimated costs beyond the trial
eriod. All of these ICER estimates compare favorably with
stimates of ICERs associated with other well-accepted
ardiovascular therapies, such as statin therapy for patients
ith coronary heart disease (30,31) and thrombolytic ther-
py in elderly patients (32).
Platelet adenosine diphosphate blockers in conjunction
ith aspirin therapy have been shown to be beneficial in the
reatment of vascular disease and in preventing thrombosis
fter PCI. In the CURE trial, clopidogrel therapy for up to
ne year prevented cardiovascular events in patients present-
ng with ACS (5). The subset of patients in the CURE trial
ho underwent PCI also derived significant benefit from
lopidogrel therapy (33). The CREDO trial (6) showed that
ffectiveness differences based on Blended costs for Framingham (left) and
origin (0.0) is a hypothetical cost-effectiveness threshold of $50,000 perand eoth ACS and non-ACS patients undergoing PCI had
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reatment. In addition, the CREDO trial found that a
oading strategy of clopidogrel followed by one year of
herapy significantly reduced death and vascular events.
lthough clopidogrel has been extensively studied with
ositive clinical results, there has been concern over its cost.
This cost effectiveness of clopidogrel in patients with
CS has been reported in multiple studies (8,9,34). Clopi-
ogrel use in ACS was cost effective in the short term from
he perspective of multiple countries based on results from
he CURE trial (19). In addition a Swedish report assessed
he long-term cost effectiveness of clopidogrel on top of
tandard therapy (including aspirin) in patients with ACS
nd showed that clopidogrel is cost effective providing an
ncremental survival of 0.12 years and an ICER of €1365
34). Two recent analyses using methodology similar to the
urrent study found clopidogrel to be cost effective in the
ong term for the CURE and PCI-CURE trials (8,9). Early
nd sustained clopidogrel therapy for one year in patients
ith ACS who underwent PCI, compared with a strategy of
o pretreatment and therapy for four weeks after PCI, had
n ICER range from $2,856/LYG to $4,775/LYG overall
nd from dominant to $935/LYG for patients undergoing
arly PCI (8). All patients with ACS, regardless of PCI, had
n ICER of $6,318 based on Framingham data and an
CER of $6,475 based on the Saskatchewan data.
In contrast to these results, a study using decision analytic
ethodology suggested that lifetime therapy with clopi-
ogrel would only be cost effective in aspirin-intolerant
atients (35). However, this study was not performed with
atient-level data, and it combined estimates of incidence
nd prevalence. This study considered therapy for life,
hich is difficult to model in cost-effectiveness studies (36).
ur study is the first, to our knowledge, to present long-
erm cost effectiveness results for clopidogrel use in all
atients undergoing PCI. A recent study (37) modeled the
ost effectiveness of clopidogrel for one year versus one
onth after PCI on a registry population and found one-
ear treatment economically favorable. The event rates were
igher in the registry patients than in the CREDO trial,
uggesting a possible larger clinical effect of clopidogrel use
n a non-trial setting.
A major strength of this analysis is that it was performed
able 6. Long-Term Cost Effectiveness, Including Cost Beyond
 Cost  Life-Years
ICER
(Cost per LY
ramingham
Medicare $1,188 0.1526 $7,786
MEDSTAT $1,199 0.1526 $7,857
Blend $1,290 0.1526 $8,454
askatchewan
Medicare $1,247 0.1920 $6,492
MEDSTAT $1,257 0.1920 $6,548
Blend $1,348 0.1920 $7,023
bbreviations as in Table 5.ith patient-level data directly from the CREDO trial. coreover, as a randomized comparison, the assessment of
oth effectiveness and cost reflect the actual exposure to
reatments independently of selection bias. In the CREDO
rial, concomitant medicine use reflected care consistent
ith American College of Cardiology/American Heart
ssociation ACS guidelines; in particular, statin,
ngiotensin-converting enzyme inhibitor, and beta blocker
se was encouraged. The CREDO trial, therefore, serves as
contemporary evaluation of the cost effectiveness of
lopidogrel and aspirin versus aspirin and placebo in pa-
ients undergoing PCI.
tudy limitations. Although this study was performed
ith resource use and clinical outcome data from a large
linical trial, it has potential limitations. The U.S. costs
ased on DRGs were applied to both American and
anadian patients and may not account for variation in
esource use between these different health systems. Use of
RGs for costing could underestimate or overestimate the
ifferences. For instance, if coronary artery bypass graft
ength of stay in Canada were longer than the U.S., resource
tilization for Canadian patients would be underestimated
f all patients were attributed the same U.S.-based DRG.
lternatively, a cost-accounting approach would allow for
ariability of costs within a DRG; however, these data were
navailable from the CREDO trial. Unless costs were
igher in one treatment arm for the same DRG, this effect
hould have yielded unbiased overall cost estimates. This
pproach may also reduce the variability in assessment of
ost differences attributable to treatment.
A societal perspective is ideally suited to a cost-
ffectiveness analysis. However, it is not feasible to measure
ny one cost from a societal perspective, thus proxies are
sed. The DRGs represent a payer cost perspective, widely
pplicable for macro hospital payments in the U.S. health
are system, whereas cost-accounting systems represent a
rovider cost perspective. Therefore, although providers
ay not consider DRGs representative of their costs, it is
erhaps a better measure of cost from a societal point of
iew. In addition, this study does not include all resource
se, in particular rehabilitation after events and outpatient
esource use. Indirect costs (lost wages or productivity) are
lso not included. These costs would most likely be higher
n the placebo arm because there were more events that
rial Period
% Dominant % Dominated % <50,000/LYG
2.0% 1.1% 96.9%
2.2% 1.0% 97.9%
1.8% 0.9% 97.1%
1.3% 0.3% 98.6%
1.9% 0.4% 98.6%
1.1% 0.2% 98.8%the T
G)ould lead to more resource consumption and more time
l
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Cost Effectiveness of Clopidogrel in PCI September 6, 2005:761–9ost from work. As a result the cost effectiveness estimates in
his analysis would be conservative. In addition, although
nclusion of forgone costs as a result of early mortality
ncreased the ICERs, the majority of bootstrap estimates
ere less than $50,000/LYG. An additional criticism may
e our inability to assess the effect of drug-eluting stents on
esource use. However, because drug-eluting stents do not
eem to affect MI or survival rates, nor do they necessarily
lter length of clopidogrel use, the current analysis is
onservative.
There are also limitations to the use of external databases
o estimate life expectancy. Improvements in medical care
ave prolonged survival in patients with vascular disease that
ay not be adequately reflected in the Framingham data-
ase. However, because there was more loss of life expec-
ancy in the placebo arm, Framingham would have under-
stimated loss of life more in the placebo arm than in the
lopidogrel arm, again making these results conservative.
askatchewan Health, however, which was based on index
ospitalizations occurring between 1990 and 1995, yielded
imilar life expectancy results as the placebo group in the
REDO trial. It is also worth noting that the uncertainty
nderlying the life expectancy estimates from Saskatchewan
nd Framingham models was not accounted for in this
nalysis. However, the two databases yielded consistent
esults, which suggest that the life expectancy estimates used
n this analysis are reasonable. Although this analysis does
ssume that the impact of events noted in the CREDO trial
ave the same prognostic impact as events from the Fra-
ingham and Saskatchewan models, there is little doubt
hat events do predict future events (38,39). If the prognos-
ic importance of events in the CREDO trial was one-half
f that in the Framingham and Saskatchewan studies, then
he ICERs would double but would still be reasonably low.
Over the last two decades, there have been vast improve-
ents in the care of patients with vascular disease. Aspirin
nd other antiplatelet agents have proven efficacy when used
ppropriately in patients undergoing PCI. This study clearly
hows that clopidogrel loading before PCI followed by one
ear of treatment is cost effective in the long term.
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